, /PRNewswire/ -- Prelude Corporation (PreludeDx ), a leader in precision diagnostics for early-stage breast cancer, announced an important advancement in the field of breast cancer care with the publication of the PREDICT study in the This comprehensive study evaluated the clinical utility of PreludeDx's DCISionRT test, a genomic biosignature designed to assess each patient's unique tumor biology in order to guide personalized treatment decisions for women with ductal carcinoma in situ (DCIS). Historically, DCIS has presented a unique challenge in both overtreatment and undertreatment of women with DCIS. The PREDICT study was designed to address the impact of the DCISionRT test on radiotherapy (RT) recommendations.
The study enrolled more than 2,000 women diagnosed with DCIS at 63 academic and community centers across the U.S. Patients were offered the DCISionRT test as part of their standard of care, and clinicians reported their treatment recommendations both before and after receiving the test results.
Importantly, the DCISionRT test result influenced a change in RT treatment recommendations in 38% of patients, and emerged as the strongest predictor of post-test RT guidance from physicians. "The PREDICT study represents a significant milestone in our understanding of how to personalize treatment for DCIS," said , President and CEO of PreludeDx. "The publication of this study in the Annals of Surgical Oncology further establishes the DCISionRT test as a valuable tool for c.
